NASDAQ:SMTI

Sanara MedTech Competitors

$30.84
-0.73 (-2.31 %)
(As of 04/12/2021 12:27 PM ET)
Add
Compare
Today's Range
$30.81
Now: $30.84
$32.16
50-Day Range
$28.36
MA: $31.64
$39.68
52-Week Range
$7.92
Now: $30.84
$53.85
Volume118 shs
Average Volume38,601 shs
Market Capitalization$234.91 million
P/E RatioN/A
Dividend YieldN/A
Beta2.43

Competitors

Sanara MedTech (NASDAQ:SMTI) Vs. SIEN, IVC, SRGA, SRGA, LAKE, and CFMS

Should you be buying SMTI stock or one of its competitors? Companies in the industry of "surgical appliances & supplies" are considered alternatives and competitors to Sanara MedTech, including Sientra (SIEN), Invacare (IVC), Surgalign (SRGA), Surgalign (SRGA), Lakeland Industries (LAKE), and Conformis (CFMS).

Sientra (NASDAQ:SIEN) and Sanara MedTech (NASDAQ:SMTI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, institutional ownership, earnings, risk and valuation.

Profitability

This table compares Sientra and Sanara MedTech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sientra-123.88%-174.05%-38.97%
Sanara MedTech-39.58%-175.36%-55.40%

Institutional and Insider Ownership

71.0% of Sientra shares are owned by institutional investors. 2.8% of Sientra shares are owned by insiders. Comparatively, 78.4% of Sanara MedTech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

Sientra has a beta of 1.81, suggesting that its stock price is 81% more volatile than the S&P 500. Comparatively, Sanara MedTech has a beta of 2.43, suggesting that its stock price is 143% more volatile than the S&P 500.

Valuation & Earnings

This table compares Sientra and Sanara MedTech's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sientra$83.70 million4.81$-106,820,000.00($2.29)-3.07
Sanara MedTech$11.77 million19.96$-2,810,000.00N/AN/A

Sanara MedTech has lower revenue, but higher earnings than Sientra.

Analyst Recommendations

This is a breakdown of current ratings for Sientra and Sanara MedTech, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sientra00403.00
Sanara MedTech0000N/A

Sientra currently has a consensus target price of $10.00, indicating a potential upside of 43.06%. Given Sientra's higher possible upside, equities analysts clearly believe Sientra is more favorable than Sanara MedTech.

Summary

Sientra beats Sanara MedTech on 7 of the 12 factors compared between the two stocks.

Invacare (NYSE:IVC) and Sanara MedTech (NASDAQ:SMTI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, institutional ownership, earnings, risk and valuation.

Profitability

This table compares Invacare and Sanara MedTech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Invacare-4.87%-8.76%-3.07%
Sanara MedTech-39.58%-175.36%-55.40%

Institutional and Insider Ownership

96.7% of Invacare shares are owned by institutional investors. 3.2% of Invacare shares are owned by insiders. Comparatively, 78.4% of Sanara MedTech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

Invacare has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500. Comparatively, Sanara MedTech has a beta of 2.43, suggesting that its stock price is 143% more volatile than the S&P 500.

Valuation & Earnings

This table compares Invacare and Sanara MedTech's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Invacare$927.96 million0.31$-53,330,000.00($1.06)-7.89
Sanara MedTech$11.77 million19.96$-2,810,000.00N/AN/A

Sanara MedTech has lower revenue, but higher earnings than Invacare.

Analyst Recommendations

This is a breakdown of current ratings for Invacare and Sanara MedTech, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Invacare00103.00
Sanara MedTech0000N/A

Invacare currently has a consensus target price of $17.00, indicating a potential upside of 103.35%. Given Invacare's higher possible upside, equities analysts clearly believe Invacare is more favorable than Sanara MedTech.

Summary

Invacare beats Sanara MedTech on 8 of the 12 factors compared between the two stocks.

Surgalign (NASDAQ:SRGA) and Sanara MedTech (NASDAQ:SMTI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, institutional ownership, earnings, risk and valuation.

Profitability

This table compares Surgalign and Sanara MedTech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Surgalign-56.07%-101.34%-18.44%
Sanara MedTech-39.58%-175.36%-55.40%

Institutional and Insider Ownership

53.5% of Surgalign shares are owned by institutional investors. 3.7% of Surgalign shares are owned by insiders. Comparatively, 78.4% of Sanara MedTech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

Surgalign has a beta of 2.21, suggesting that its stock price is 121% more volatile than the S&P 500. Comparatively, Sanara MedTech has a beta of 2.43, suggesting that its stock price is 143% more volatile than the S&P 500.

Valuation & Earnings

This table compares Surgalign and Sanara MedTech's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Surgalign$308.38 million0.72$-211,640,000.00($0.16)-12.63
Sanara MedTech$11.77 million19.96$-2,810,000.00N/AN/A

Sanara MedTech has lower revenue, but higher earnings than Surgalign.

Analyst Recommendations

This is a breakdown of current ratings for Surgalign and Sanara MedTech, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Surgalign00403.00
Sanara MedTech0000N/A

Surgalign currently has a consensus target price of $4.3333, indicating a potential upside of 113.46%. Given Surgalign's higher possible upside, equities analysts clearly believe Surgalign is more favorable than Sanara MedTech.

Summary

Surgalign beats Sanara MedTech on 7 of the 12 factors compared between the two stocks.

Surgalign (NASDAQ:SRGA) and Sanara MedTech (NASDAQ:SMTI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, institutional ownership, earnings, risk and valuation.

Valuation & Earnings

This table compares Surgalign and Sanara MedTech's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Surgalign$308.38 million0.72$-211,640,000.00($0.16)-12.63
Sanara MedTech$11.77 million19.96$-2,810,000.00N/AN/A

Sanara MedTech has lower revenue, but higher earnings than Surgalign.

Volatility and Risk

Surgalign has a beta of 2.21, suggesting that its stock price is 121% more volatile than the S&P 500. Comparatively, Sanara MedTech has a beta of 2.43, suggesting that its stock price is 143% more volatile than the S&P 500.

Profitability

This table compares Surgalign and Sanara MedTech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Surgalign-56.07%-101.34%-18.44%
Sanara MedTech-39.58%-175.36%-55.40%

Analyst Recommendations

This is a breakdown of current ratings for Surgalign and Sanara MedTech, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Surgalign00403.00
Sanara MedTech0000N/A

Surgalign currently has a consensus target price of $4.3333, indicating a potential upside of 113.46%. Given Surgalign's higher possible upside, equities analysts clearly believe Surgalign is more favorable than Sanara MedTech.

Institutional and Insider Ownership

53.5% of Surgalign shares are owned by institutional investors. 3.7% of Surgalign shares are owned by insiders. Comparatively, 78.4% of Sanara MedTech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Surgalign beats Sanara MedTech on 7 of the 12 factors compared between the two stocks.

Sanara MedTech (NASDAQ:SMTI) and Lakeland Industries (NASDAQ:LAKE) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, dividends, risk, institutional ownership and earnings.

Valuation and Earnings

This table compares Sanara MedTech and Lakeland Industries' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sanara MedTech$11.77 million19.96$-2,810,000.00N/AN/A
Lakeland Industries$107.81 million2.12$3.28 million$0.4563.27

Lakeland Industries has higher revenue and earnings than Sanara MedTech.

Volatility and Risk

Sanara MedTech has a beta of 2.43, suggesting that its stock price is 143% more volatile than the S&P 500. Comparatively, Lakeland Industries has a beta of 0.03, suggesting that its stock price is 97% less volatile than the S&P 500.

Profitability

This table compares Sanara MedTech and Lakeland Industries' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sanara MedTech-39.58%-175.36%-55.40%
Lakeland Industries18.93%28.75%24.67%

Analyst Ratings

This is a breakdown of current recommendations and price targets for Sanara MedTech and Lakeland Industries, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sanara MedTech0000N/A
Lakeland Industries00203.00

Lakeland Industries has a consensus target price of $31.3333, indicating a potential upside of 9.29%. Given Lakeland Industries' higher possible upside, analysts plainly believe Lakeland Industries is more favorable than Sanara MedTech.

Institutional & Insider Ownership

70.8% of Lakeland Industries shares are owned by institutional investors. 78.4% of Sanara MedTech shares are owned by insiders. Comparatively, 4.9% of Lakeland Industries shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Lakeland Industries beats Sanara MedTech on 9 of the 12 factors compared between the two stocks.

Sanara MedTech (NASDAQ:SMTI) and Conformis (NASDAQ:CFMS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, dividends, risk, institutional ownership and earnings.

Valuation and Earnings

This table compares Sanara MedTech and Conformis' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sanara MedTech$11.77 million19.96$-2,810,000.00N/AN/A
Conformis$77.43 million2.01$-28,480,000.00($0.44)-1.94

Sanara MedTech has higher earnings, but lower revenue than Conformis.

Volatility and Risk

Sanara MedTech has a beta of 2.43, suggesting that its stock price is 143% more volatile than the S&P 500. Comparatively, Conformis has a beta of 1.63, suggesting that its stock price is 63% more volatile than the S&P 500.

Profitability

This table compares Sanara MedTech and Conformis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sanara MedTech-39.58%-175.36%-55.40%
Conformis-32.11%-174.01%-32.59%

Analyst Ratings

This is a breakdown of current recommendations and price targets for Sanara MedTech and Conformis, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sanara MedTech0000N/A
Conformis01302.75

Conformis has a consensus target price of $2.3333, indicating a potential upside of 176.43%. Given Conformis' higher possible upside, analysts plainly believe Conformis is more favorable than Sanara MedTech.

Institutional & Insider Ownership

30.2% of Conformis shares are owned by institutional investors. 78.4% of Sanara MedTech shares are owned by insiders. Comparatively, 3.2% of Conformis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Conformis beats Sanara MedTech on 8 of the 12 factors compared between the two stocks.


Sanara MedTech Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Sientra logo
SIEN
Sientra
1.6$7.03-2.0%$410.65 million$83.70 million-3.95
Invacare logo
IVC
Invacare
1.6$8.36-1.1%$284.69 million$927.96 million-6.80
Surgalign logo
SRGA
Surgalign
1.7$2.02-1.5%$226.05 million$308.38 million-1.12
Surgalign logo
SRGA
Surgalign
1.4$2.02-1.5%$226.05 million$308.38 million-1.12
Lakeland Industries logo
LAKE
Lakeland Industries
1.4$28.47-1.4%$225.20 million$107.81 million8.09Upcoming Earnings
Conformis logo
CFMS
Conformis
1.3$0.85-5.1%$163.81 million$77.43 million-2.51
ReWalk Robotics logo
RWLK
ReWalk Robotics
1.4$1.96-8.7%$98.18 million$4.87 million-1.56
CollPlant Biotechnologies logo
CLGN
CollPlant Biotechnologies
1.1$13.47-2.4%$78.25 million$2.32 million-6.74Gap Up
Predictive Oncology logo
POAI
Predictive Oncology
1.3$1.35-10.8%$72.70 million$1.41 million-0.21Gap Down
AHPI
Allied Healthcare Products
0.5$4.47-2.5%$18.37 million$31.89 million0.00
NanoVibronix logo
NAOV
NanoVibronix
0.5$0.96-3.8%$13.39 million$530,000.00-1.61
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.